PART 350—ANTIPERSPIRANT DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE Authority: 21 U.S.C. 321, 351, 352, 353, 355, 360, 371. Source: 68 FR 34291, June 9, 2003, unless otherwise noted. Subpart A—General Provisions § 350.1 Scope. (a) An over-the-counter antiperspirant drug product in a form suitable for topical administration is generally recognized as safe and effective and is not misbranded if it meets each condition in this part and each general condition established in § 330.1 of this chapter. (b) References in this part to regulatory sections of the Code of Federal Regulations are to chapter I of title 21 unless otherwise noted. § 350.3 Definition. As used in this part: Antiperspirant. Subpart B—Active Ingredients § 350.10 Antiperspirant active ingredients. The active ingredient of the product consists of any of the following within the established concentration and dosage formulation. Where applicable, the ingredient must meet the aluminum to chloride, aluminum to zirconium, and aluminum plus zirconium to chloride atomic ratios described in the U.S. Pharmacopeia-National Formulary. The concentration of ingredients in paragraphs (b) through (j) of this section is calculated on an anhydrous basis, omitting from the calculation any buffer component present in the compound, in an aerosol or nonaerosol dosage form. The concentration of ingredients in paragraphs (k) through (r) of this section is calculated on an anhydrous basis, omitting from the calculation any buffer component present in the compound, in a nonaerosol dosage form. The labeled declaration of the percentage of the active ingredient should exclude any water, buffer components, or propellant. (a) Aluminum chloride up to 15 percent, calculated on the hexahydrate form, in an aqueous solution nonaerosol dosage form. (b) Aluminum chlorohydrate up to 25 percent. (c) Aluminum chlorohydrex polyethylene glycol up to 25 percent. (d) Aluminum chlorohydrex propylene glycol up to 25 percent. (e) Aluminum dichlorohydrate up to 25 percent. (f) Aluminum dichlorohydrex polyethylene glycol up to 25 percent. (g) Aluminum dichlorohydrex propylene glycol up to 25 percent. (h) Aluminum sesquichlorohydrate up to 25 percent. (i) Aluminum sesquichlorohydrex polyethylene glycol up to 25 percent. (j) Aluminum sesquichlorohydrex propylene glycol up to 25 percent. (k) Aluminum zirconium octachlorohydrate up to 20 percent. (l) Aluminum zirconium octachlorohydrex gly up to 20 percent. (m) Aluminum zirconium pentachlorohydrate up to 20 percent. (n) Aluminum zirconium pentachlorohydrex gly up to 20 percent. (o) Aluminum zirconium tetrachlorohydrate up to 20 percent. (p) Aluminum zirconium tetrachlorohydrex gly up to 20 percent. (q) Aluminum zirconium trichlorohydrate up to 20 percent. (r) Aluminum zirconium trichlorohydrex gly up to 20 percent. Subpart C—Labeling § 350.50 Labeling of antiperspirant drug products. (a) Statement of identity. (b) Indications. (1) For any product, the labeling states [select one of the following: “decreases,” “lessens,” or “reduces”] “underarm” [select one of the following: “dampness,” “perspiration,” “sweat,” “sweating,” or “wetness”]. (2) The labeling may state “also [select one of the following: ‘decreases,’ ‘lessens,’ or ‘reduces’] underarm [select one of the following: ‘dampness,’ ‘perspiration,’ ‘sweat,’ ‘sweating,’ or ‘wetness’] due to stress”. (3) For products that demonstrate standard effectiveness (20 percent sweat reduction) over a 24-hour period, the labeling may state [select one of the following: “all day protection,” “lasts all day,” “lasts 24 hours,” or “24 hour protection”]. (4) For products that demonstrate extra effectiveness (30 percent sweat reduction), the labeling may state “extra effective”. (5) Products that demonstrate extra effectiveness (30 percent sweat reduction) sustained over a 24-hour period may state the claims in paragraphs (b)(3) and (b)(4) of this section either individually or combined, e.g., “24 hour extra effective protection”, “all day extra effective protection,” “extra effective protection lasts 24 hours,” or “extra effective protection lasts all day”. (c) Warnings. (1) “Do not use on broken skin”. (2) “Stop use if rash or irritation occurs”. (3) “Ask a doctor before use if you have kidney disease”. (4) For products in an aerosolized dosage form. 1 1 (ii) The warning required by § 369.21 of this chapter for drugs in dispensers pressurized by gaseous propellants. (d) Directions. Effective Date Note: At 69 FR 61149, Oct. 15, 2004, the limitation of the enhanced duration claim to 24 hours (21 CFR 350.50 (b)(3) and (b) (5)) was stayed until further notice. Subpart D—Guidelines for Effectiveness Testing § 350.60 Guidelines for effectiveness testing of antiperspirant drug products. An antiperspirant in finished dosage form may vary in degree of effectiveness because of minor variations in formulation. To assure the effectiveness of an antiperspirant, the Food and Drug Administration is providing guidelines that manufacturers may use in testing for effectiveness. These guidelines are on file in the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. These guidelines are available on the FDA's web site at http://www.fda.gov/cder/otc/index.htm http://www.fda.gov. [68 FR 34291, June 9, 2003, as amended at 76 FR 31470, June 1, 2011; 79 FR 68115, Nov. 14, 2014; 88 FR 45066, July 14, 2023]